Tempus AI, Inc. and Blood Cancer United announced a partnership to create a comprehensive real‑world registry for pediatric acute myeloid leukemia (pAML). The registry will collect clinical, genomic, and treatment outcome data from participating hospitals and research centers, providing a platform for researchers and clinicians to track long‑term outcomes and improve care pathways for children with AML.
The collaboration will accelerate biomarker discovery, clinical trial matching, and therapeutic development for this rare and aggressive disease. By adding pAML data to its precision‑medicine platform, Tempus expands its reach into an underserved patient population and strengthens its position as a leader in AI‑driven oncology research.
Blood Cancer United, which rebranded from The Leukemia & Lymphoma Society in 2025, is the largest nonprofit dedicated to blood cancer patient support. Tempus has a history of strategic collaborations with major pharmaceutical companies—including Merck, AstraZeneca, and Pathos AI—and has bolstered its capabilities through acquisitions such as Ambry Genetics, Deep 6 AI, and Paige. The partnership fits within a competitive landscape of tech‑driven oncology firms that rely on multimodal data and AI analytics.
The partnership positions Tempus to capture rare disease data, enhance its AI models, and open new licensing opportunities. It also strengthens the company’s market position and supports future clinical trials, reinforcing its strategy of building a multimodal data ecosystem that fuels AI algorithms and generates new revenue streams.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.